Robert Norman Young

8.7k citations

159 papers · 7.5k · 1 hit paper · h-index 40

Impact in

Pharmacology top 0.5%
- Inflammatory mediators and NSAID effects
Biochemistry top 1%
- Eicosanoids and Hypertension Pharmacology

Papers in

Pharmacology 15
- Inflammatory mediators and NSAID effects 15
Biochemistry 6
- Eicosanoids and Hypertension Pharmacology 6

Co-authors: A. W. Ford‐Hutchinson (6 shared papers)Michael J. Gresser (1 shared paper)Joshua Rokach (12 shared papers)Yves Girard (13 shared papers)Robert J. Zamboni (17 shared papers)Yongxin Han (4 shared papers)Jacques Yves Gauthier (10 shared papers)Paul Masson (10 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (27 papers)Tetrahedron Letters (12 papers)Journal of Medicinal Chemistry (10 papers)Canadian Journal of Physiology and Pharmacology (7 papers)Bioorganic & Medicinal Chemistry (6 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Robert Norman Young

157 papers receiving 6.9k citations

Robert Norman Young's Hit Papers

align trajectories log scale

The promise and peril of chemical probes 2015 · 673 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2015 Nature Chemical Biology

Peers

Countries citing papers authored by Robert Norman Young

Since Specialization

Citations

This map shows the geographic impact of Robert Norman Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Norman Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Norman Young more than expected).

Fields of papers citing papers by Robert Norman Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Norman Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Norman Young. The network helps show where Robert Norman Young may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Norman Young, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Norman Young Line = papers co-authored together Robert Norman Young links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 159 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The promise and peril of chemical probes Nature Chemical Biology ·C.H. Arrowsmith, James E. Audia, Christopher P. Austin, Jonathan B. Baell, Julian Blagg, C. Bountra, Paul E. Brennan, Peter J. Brown Hit paper breakdown →	2015	673
2	The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Bioorganic & Medicinal Chemistry Letters ·Petpiboon Prasit, Z Wang, Christine Brideau, Chi‐Chung Chan, Stella E. Charleson, Wanda A. Cromlish, Diane Ethier, Jilly F. Evans	1999	409
3	Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 Journal of Pharmacology and Experimental Therapeutics ·Denis Riendeau, M. David Percival, Christine Brideau, Stella E. Charleson, Daniel Dubé, Diane Ethier, Jean‐Pierre Falgueyret, Richard W. Friesen	2001	404
4	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorganic & Medicinal Chemistry Letters ·Jacques Yves Gauthier, Nathalie Chauret, Wanda A. Cromlish, Le T. Duong, Jean‐Pierre Falgueyret, Donald B. Kimmel, Sonia Lamontagne, Serge Léger	2008	400
5	5-LIPOXYGENASE Annual Review of Biochemistry ·A. W. Ford‐Hutchinson, Michael J. Gresser, Robert Norman Young	1994	344
6	Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor British Journal of Pharmacology ·Denis Riendeau, M. David Percival, Sue Boyce, Christine Brideau, Stella E. Charleson, Wanda A. Cromlish, Diane Ethier, Jilly F. Evans	1997	300
7	L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor Canadian Journal of Physiology and Pharmacology ·John W. Gillard, A W Ford‐Hutchinson, Chi-Chung Chan, Stella E. Charleson, Aidan Foster, Réjean Fortin, Serge Léger, C. S. McFarlane	1989	296
8	Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530 Bioorganic & Medicinal Chemistry Letters ·Daniel Dubé, Marc Blouin, Christine Brideau, Chi‐Chung Chan, Diane Ethier, Jean‐Pierre Falgueyret, Richard W. Friesen, Yves Girard	1998	251
9	Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist Canadian Journal of Physiology and Pharmacology ·Thomas R. Jones, Robert J. Zamboni, Michel L. Belley, L. Charette, A. W. Ford‐Hutchinson, Richard Frenette, J-Y. Gauthier, Serge Léger	1989	243
10	Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. The Journal of Immunology ·Edward C. Hayes, Donna L. Lombardo, Yves Girard, Alan L. Maycock, Joshua Rokach, A S Rosenthal, Robert Norman Young, Robert W. Egan	1983	187
11	Prostaglandin Receptor EP 4 Mediates the Bone Anabolic Effects of PGE 2 Molecular Pharmacology ·M. Machwate, Satoru Harada, Chih‐Tai Leu, G. Seedor, Marc Labelle, Nicolas Lachance, Nicole Sawyer, Deborah Slipetz	2001	154
12	Discovery of a Potent and Selective Prostaglandin D2 Receptor Antagonist, [(3R)-4-(4-Chloro- benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524) Journal of Medicinal Chemistry ·Claudio F. Sturino, Gary P. O’Neill, Nicolas Lachance, Michael J. Boyd, Carl Berthelette, Marc Labelle, Lianhai Li, Bruno Roy	2007	153
13	2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Richard W. Friesen, Christine Brideau, Chi‐Chung Chan, Stella E. Charleson, Denis Deschênes, Daniel Dubé, Diane Ethier, Réjean Fortin	1998	116
14	Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? European Journal of Medicinal Chemistry ·Robert Norman Young	1999	114
15	Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative Verteporfin Journal of Biological Chemistry ·Elizabeth Donohue, Andrew Norman Tovey, A. Wayne Vogl, Steve Arns, Ethan D. Sternberg, Robert Norman Young, Michel Roberge	2010	113
16	Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor Canadian Journal of Physiology and Pharmacology ·Christine Brideau, Christine S. Chan, Stella E. Charleson, Jilly F. Evans, A W Ford‐Hutchinson, Réjean Fortin, John W. Gillard, Julie Guay	1992	104
17	The synthesis of a leukotriene with SRS-like activity Tetrahedron Letters ·Joshua Rokach, Yves Girard, Yvan Guindon, Joseph G. Atkinson, M. Larue, Robert Norman Young, Paul Masson, George Holme	1980	94
18	Silicon directed ipso-substitution of polymer bound arylsilanes: Preparation of biaryls via the Suzuki cross-coupling reaction Tetrahedron Letters ·Yongxin Han, Shawn D. Walker, Robert Norman Young	1996	86
19	Design and Synthesis of Tri-Ring P3 Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K Journal of Medicinal Chemistry ·Clifford Bryant, Dan-Xiong Wang, Eduardo L. Setti, Robert M. Rydzewski, Shankar Venkatraman, Zong‐Qiang Tian, Leland C. Burrill, Rohan V. Mendonca	2005	86
20	Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives Journal of Medicinal Chemistry ·Ravi S. N. Munuganti, Eric Leblanc, Peter Axerio-Cilies, Christophe Labrière, Kate Frewin, Kriti Singh, Mohamed D.H. Hassona, Nathan A. Lack	2013	83

About Robert Norman Young

Robert Norman Young is a scholar working on Pharmacology, Biochemistry, Organic Chemistry, Molecular Biology and Cancer Research, having authored 159 papers that have together received 7.5k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (15 papers), Phosphodiesterase function and regulation (9 papers), Eicosanoids and Hypertension Pharmacology (6 papers), Autophagy in Disease and Therapy (6 papers), Asthma and respiratory diseases (4 papers), Protease and Inhibitor Mechanisms (4 papers), Cystic Fibrosis Research Advances (4 papers) and Bone health and osteoporosis research (3 papers). The work is most often cited by research in Pharmacology (909 citations), Biochemistry (184 citations), Organic Chemistry (935 citations), Computational Theory and Mathematics (332 citations) and Pharmaceutical Science (130 citations). Robert Norman Young has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include A. W. Ford‐Hutchinson, Michael J. Gresser, Joshua Rokach, Yves Girard, Robert J. Zamboni, Yongxin Han, Jacques Yves Gauthier, Paul Masson, Richard Frenette and Alan L. Maycock. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Tetrahedron Letters, Journal of Medicinal Chemistry, Canadian Journal of Physiology and Pharmacology and Bioorganic & Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Robert Norman Young

Impact in

Papers in i

In The Last Decade

Robert Norman Young

Robert Norman Young's Hit Papers

Peers

Countries citing papers authored by Robert Norman Young

Fields of papers citing papers by Robert Norman Young

All Works

About Robert Norman Young

Explore authors with similar magnitude of impact

Papers in